|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From Pediatric Hematology and Oncology, University
Children's Hospital, Hamburg, Germany; Lab Association Keeser, Arndt
and Partners, Coagulation Lab, Hamburg, Germany; Searle/Monsanto,
Investigative and Discovery Pathology, St Louis, MO; the Scripps
Research Institute, La Jolla, CA; and the Institute of Experimental
Hematology and Transfusion Medicine, University of Bonn, Bonn, Germany.
Dimerization defects of von Willebrand factor (vWF) protomers
underlie von Willebrand disease (vWD) type 2A, subtype IID (vWD 2A/IID), and corresponding mutations have been identified at the 3' end
of the vWF gene in exon 52. This study identified and expressed 2 additional mutations in this region, a homozygous defect in a patient
with vWD type 3 (C2754W) and a heterozygous frameshift mutation
(8566delC) in a patient with vWD type 2A, subtype IIE. Both mutations
involve cysteine residues that we propose are possibly essential for
dimerization. To prove this hypothesis, transient recombinant
expression of each of the 2 mutations introduced in the
carboxy-terminal vWF fragment II and in the complete vWF
complementary DNA, respectively, were carried out in COS-7 cells
and compared with expression of vWD 2A/IID mutation C2773R and the
wild-type (WT) sequence in COS-7 cells. Recombinant WT vWF fragment II
assembled correctly into a dimer, whereas recombinant mutant fragments
were monomeric. Homozygous expression of recombinant mutant full-length vWF resulted in additional dimers, probably through disulfide bonding
at the amino-terminal multimerization site, whereas recombinant WT vWF correctly assembled into multimers. Coexpression of
recombinant mutant and recombinant WT vWF reproduced the multimer
patterns observed in heterozygous individuals. Our results suggest that a common defect of vWF biosynthesis Von Willebrand disease (vWD) is a heterogeneous
hereditary bleeding disorder caused by diverse molecular defects of von
Willebrand factor (vWF) that often correlate with the observed
phenotype. Although deletions, nonsense mutations, and frameshift
mutations are responsible for most cases of vWD type 3 (vWD
3),1-3 because of the virtual absence of vWF protein in
the patient's plasma and platelets, some mutations alter particular
functions of vWF. Functions affected by these mutations include the
binding to platelet glycoprotein Ib in vWD type 2B4 and
the factor VIII (FVIII) binding activity of vWF in vWD type
2N.5 Several vWF defects are consequential to impaired
posttranslation biosynthesis, including defective dimerization of vWF
monomers in vWD 2A, subtype IID (vWD 2A/IID),6 defective
multimerization in vWD 2A, subtype IIC (vWD 2A/IIC),7,8
and defective intracellular transport and secretion of
intermediate and high-molecular-weight multimers (HMWM) in vWD 2A,
subtype IIA (vWD 2A/IIA; mutation group 1).9 Mutations
associated with vWD 2A/IIA (group 2) lead to enhanced proteolysis of
vWF multimers in plasma9 by a specific
metalloprotease.10 The vWD subtypes IIA, IIC, IID, IIE,
IIF, IIG, and IIH, have been combined to form a common type, vWD type
2A, which comprises all variants lacking HMWM in plasma.11
The single exception is type 2B, in which the absence of plasma HMWM
reflects an enhanced binding of HMWM to glycoprotein Ib followed by
clearance from the circulation.4
We previously demonstrated that the underlying cause of the vWD 2A/IID
phenotype is a heterozygous dimerization defect at the carboxy-terminal
of vWF.6 We here report on the expression and
characterization of 2 additional mutations, which are located in the
same amino-terminal dimerization domain of vWF. One mutation leads to
vWD 2A, subtype IIE (vWD 2A/IIE), which is characterized by a mild to
moderate bleeding tendency, decreased large vWF multimers, and
decreased proteolysis of vWF.12 The other mutation results in vWD 3. Both mutations involve cysteine residues that may be essential for dimerization.
Patients
Diagnosis of vWD
Mutation screening Nucleotides of the vWF complementary DNA (cDNA) sequence are numbered from the major transcription cap site (+1) located 250 nucleotides upstream of the first nucleotide in the ATG initiation codon. Amino acid residues are numbered from the ATG initiation codon (residue 1) to the carboxy-terminal lysine (residue 2813) of pre-pro-vWF. Correspondence with residues in the mature vWF sequence is obtained by subtracting 763 from the residue number of pre-pro-vWF.High-molecular-weight genomic DNA was prepared from frozen buffy coats by using standard techniques21 and used in amplification of vWF gene sequences by polymerase chain reaction (PCR).22 PCR was done in a Trio-Thermoblock device (Biometra, Göttingen, Germany) using reagents and Taq polymerase from Gibco BRL (Gaithersburg, MD). Mutation screening was carried out through amplification of single exons flanked by sufficient intron sequences to also allow detection of splice-site mutations.6 Primers that differed from the pseudogenic sequences were designed to avoid amplification of the pseudogene.23 DNA from a patient with a complete homozygous deletion of the vWF gene served as a negative control. PCR was combined with analysis of single-strand conformation polymorphisms (SSCP)24 and heteroduplex analysis25 of exons 2 through 52, as described previously.6 The aberrant PCR products were sequenced by using phosphorus 33-labeled dideoxynucleoside triphosphate terminators (Amersham, Braunschweig, Germany). The mutations were confirmed by sequencing both strands. In the case of the frameshift mutation 8566delC in the patient with vWD 2A/IIE, the individual alleles were cloned into pCR-Script Amp SK(+) (Stratagene, Heidelberg, Germany) before sequencing, and this was followed by amplification in Epicurian XL1-Blue MRF' Kan supercompetent cells according to the manufacturer's instructions. Mutation screening in this patient was further extended by sequencing all coding exons together with respective flanking intron regions. Haplotypes were established by analyzing published intragenic polymorphisms26 (and http://mmg2.im.med.umich.edu/vWF) and SSCP detected during mutation screening. Expression studies Posttranslational processing of vWF monomers includes dimerization by disulfide bonding at the cysteine-rich carboxy-terminal and polymerization to multimers of different size at the amino-terminal. Because it was shown that disulfide bonding at the amino-terminal is independent of dimerization at the carboxy-terminal,27 we hypothesized that recombinant expression of a dimerization defect by using full-length vWF cDNA would nevertheless result in the formation of dimers by disulfide bonding at the intact amino-terminal. Following that strategy, we expressed the carboxy-terminal proteolytic vWF fragment II to assess the isolated dimerization process as previously described6 and compared the results with those obtained by expression of full-length vWF cDNA. Both mutations were compared with the wild type (WT) and the previously described vWD 2A/IID defect.6Recombinant expression of the carboxy-terminal vWF fragment II In vitro mutagenesis of the plasmid pJB6, containing the DNA sequence coding for vWF fragment II, was carried out as described previously.6 Deviating from the originally described transfer into baculovirus, we used the mammalian expression vector pRc cytomegalovirus (pRc.CMV; Invitrogen, Leek, The Netherlands) for transfection of COS-7 cells for all mutants, including the vWD 2A/IID defect and the WT. The mutant and WT inserts were cut with XhoI, and the cohesive ends were blunted by T4 polymerase. Subsequently, the inserts were digested with NotI. pRc.CMV was cut with HindIII, and the cohesive ends were blunted by T4 polymerase. The vector was digested with NotI, and this was followed by ligation with the insert.In the case of the vWD 2A/IIE mutant, the 3' untranslated region (UTR)
of pJB6 did not extend far enough to include the novel stop codon,
which was 34 codons further downstream. Therefore, 2 PCR fragments
overlapping at 65 base pairs, one including the 5' end of the pJB6
insert and the vWD 2A/IIE frameshift mutation 8566delC (template, pJB6;
sense, M13 reverse primer; antisense, 5'-TGG TAC ACA ACA GAG CCA TTG
G-3'; and annealing temperature, 48°C) and the other including the 3'
UTR down to nucleotide 38/1071 of the published sequence28
(template, genomic DNA; sense, 5'-TCT CCG ACA CGG ACG GAG CCC-3';
antisense, 5'-ATT GCG GCC GC TCA
GAA GGG CAC AAG AGC AGA AC-3' [underlining indicates NotI
site]; and annealing temperature, 60°C) were joined by a third PCR
(sense, M13 reverse primer; antisense, 5'-ATT GCG
GCC GC TCA GAA GGG CAC AAG AGC AGA AC-3'
[underlining indicates NotI site]; and annealing temperature, 48°C). This combined PCR product was digested with XhoI and NotI and cloned into pBS/KS( The expression vector pRc.CMV was digested with HindIII, and the cohesive ends were filled in by T4 polymerase. The vector was subsequently digested with NotI, and this was followed by ligation with the insert of pTO1. After the correct ligation was confirmed by sequencing, the plasmids were cloned into Epicurian XL1-Blue MRF' Kan. Plasmids were purified by using the Endofree Plasmid Maxi Kit (Qiagen, Hilden, Germany). COS-7 cells (4 × 105; DSMZ, Braunschweig, Germany) were transiently transfected with mutant and WT fragment II DNA (10 µg each) by using the Lipofectamine Plus Kit (Life Technologies, Paisley, United Kingdom). The cells, adapted to serum-free medium (high-glucose Dulbecco modified Eagle medium and 2% Ultroser G; Life Technologies), were grown for 60 hours. vWF product was secreted in the medium and analyzed by SDS-electrophoresis in 6% polyacrylamide gels25 without prior concentration under nonreducing conditions and after reduction by dithiothreitol (DTT; 25 mM). Electrophoretic bands were visualized by using luminescent immunoblotting.19 Recombinant homozygous expression of full-length vWF cDNA The origin of the full-length vWF cDNA was the plasmid vWF-PMT229 (67122; American Type Culture Collection). The vWF cDNA insert was obtained by EcoRI digestion and transferred into the EcoRI site of pBS/KSY( ), a modified
pBS/KS() vector with an additional NotI site and lacking
the BamHI and XhoI sites (a kind gift of Y. Hashimoto). After NotI digestion, the insert was transferred into the NotI site of the expression vector pcDNA3.1
Hygro() (Invitrogen). The resulting plasmid was designated
vWF-pcDNA3.1. This vector has an EcoRV site that was used
together with an vWF intragenic EcoRV site to cut out a
small 3' portion of the vWF gene. Mutant 3' fragments were then
produced by PCR using the 2 different mutant pJB6 vectors and the
mutant pTO1 vector as templates (sense primer, 5'-GAA GAG GGT CAC AGG
CTG CC-3'; antisense primer, M13-20; and annealing temperature,
48°C). The PCR products were digested with SacI, and this
was followed by filling in the cohesive ends and subsequent digestion
with EcoRV. The resulting inserts were ligated to the large
5' EcoRV-digested vWF-pcDNA3.1 fragment. The ligation sites
and the PCR-amplified fragments were sequenced to exclude involuntarily
introduced mutations and to select constructs with the correct orientation.
Epicurian XL1-Blue MRF' Kan supercompetent cells were transformed with mutant or WT vWF-pcDNA3.1. Plasmids were purified by using the Endofree Plasmid Maxi Kit (Qiagen). COS-7 cells (4 × 105) were transiently transfected with 10 µg mutant or WT full-length vWF cDNA by using the method described above. The serum-free medium was concentrated in Centricon tubes to one tenth of the original volume before further analysis in a high-resolution SDS-agarose gel18 under nonreducing and reducing conditions. Electrophoretic bands were visualized by using luminescent immunoblotting.19 Recombinant coexpression of WT and mutant full-length vWF cDNA The same methods were used for cotransfection with WT and mutant full-length vWF cDNA (10 µg of each). To compensate for a possible lower translation efficiency of mutant sequences, 20 µg of a 1:1 proportion of WT to mutant plasmid; 1:3 proportions for all 3 mutants; and 1:9, 1:19, and 1:39 proportions for recombinant vWF 2A/IIE were used. The resulting recombinant vWF proteins were analyzed by multimer analysis in a medium-resolution SDS-agarose gel.18,19Protein truncation assay As the consequence of a frameshift mutation, the 8566delC product was predicted to be extended because of disruption of the original stop codon and the presence of a newly generated stop codon located 34 codons further downstream. This elongated product was demonstrated through a unique application of an in vitro protein truncation assay (Boehringer Mannheim, Germany) originally designed for detecting truncating nonsense or frameshift mutations.30 Following the supplier's recommendations, we amplified a portion of the 3' cDNA end, starting with the first codon of exon 48 (codon 2630) by using the sense primer 5'-gga tcc taa tac gac tca cta tag gaa cag acc acc ATG GGT TAC AAG GAA GAA AAT AAC ACA GGT GAA TGT TGT GGG-3' and the antisense vector primer M13-20. (Nucleotides of the sense primer, written in lowercase letters, represent the sequence for a T7 promotor and a Kozak consensus sequence; uppercase letters represent the coding sequence, with the vWF-specific sequence underlined.) The annealing temperature was 48°C. As templates, we used pJB6 for the WT sequence and pTO1 for the mutant sequence. In translating, we expected a peptide of 184 amino acids for the WT sequence and a peptide of 218 amino acids for the mutant sequence.
Diagnosis of vWD 2A/IIE and vWD 3 Hemostasis variables in patients and their relatives are shown in Table 1. The diagnosis of vWD 2A/IIE in patient 0103 was based on multimer analysis of vWF, which found absence of the triplet structure and absence of HMWM from both plasma and platelets. The fastest migrating electrophoretic band was not pronounced12 (Figure 1), which is in contrast to findings in vWD 2A/IIC. The markedly reduced vWF:Ag levels in the patient and the low-normal vWF:Ag levels in the patient's mother suggest compound heterozygosity for a qualitative and quantitative defect.
In the patient with vWD 3, vWF:Ag levels in both plasma and platelets were below the detection limit of the enzyme-linked immunosorbent assay used. The results of a multimer analysis were consistent with vWD 3. After obtaining knowledge of the underlying mutation, we repeated the multimer analysis of the patient's platelets with higher sensitivity and detected low-molecular-weight multimers. Levels of vWF:Ag were decreased in both the patient's parents (Table 1), and multimer analysis revealed faint extra intervening bands between individual multimers (Figure 1). Identification of candidate mutations In the patient with vWD 2A/IIE, but not in her parents, we identified a novel heterozygous mutation of the vWF gene31 that consisted of a single base deletion (8566delC) in exon 52 (Figure 2). The resulting frameshift predicted a vWF monomer that was 34 amino acids longer than the WT. The first amino acid affected by the frameshift was cysteine 2773, which is mutated in vWD 2A/IID.6 Intragenic vWF marker alleles analyzed in the patient and her parents confirmed paternity, thereby suggesting a de novo mutation. Markedly decreased vWF:Ag in the patient (0.07 U/mL) and low-normal vWF:Ag levels in her mother (0.62 U/mL) suggested an additional quantitative defect. However, although we sequenced all 51 coding exons and flanking intron regions of the vWF gene, we did not identify additional mutations.
Mutation screening of the patient with vWD 3 revealed a novel homozygous missense mutation (8512T>G) in exon 52 that predicted the amino acid exchange of cysteine 2754 for a tryptophane (C2754W). This mutation was present in heterozygous form in both parents (Figure 2).31 Protein truncation assay The vWD 2A/IIE frameshift mutation 8566delC predicted an elongated translation product, which the results of the in vitro protein truncation assay confirmed. The predicted WT product was a peptide of 184 amino acids (including the first ATG), whereas the predicted mutant product corresponded to a peptide of 218 amino acids (Figure 3). Along with this elongation, the mutation predicted the loss of 6 cysteines from the WT amino acid sequence and the generation of 7 cysteines at other positions.
Recombinant expression of the carboxy-terminal vWF fragment II Recombinant expression of the carboxy-terminal of vWF fragment II in COS-7 cells resulted in monomeric fragments for all 3 recombinant mutant peptides. Dimerized product was observed only with the recombinant WT peptide and could be reduced to a monomer by DTT (Figure 4).
Recombinant homozygous expression of full-length vWF cDNA Expression of the recombinant mutant full-length vWF in COS-7 cells resulted in vWF monomers and dimers for all 3 mutations. Additionally, fainter bands in the range of tetramers were observed. A complete set of multimers was observed in the recombinant WT vWF (Figure 5A). Under reducing conditions, the WT and mutant vWF proteins had a single band of monomer size. Relative to a plasma pool, vWF:Ag of recombinant WT vWF was 20.7%, that of recombinant C2754W vWF was 4.9%, that of recombinant C2773R vWF was 14.6%, and that of recombinant 8566delC vWF was 1.8%. The FVIII binding activity of recombinant WT vWF was 90%, and that of the mutant molecules C2754W, 8566delC, and C2773R, was 80%, 85%, and 90%, respectively. In contrast, vWF:CBA was 80% in the recombinant WT vWF but below the limit of detection in all 3 mutants.
Recombinant coexpression of WT and mutant full-length vWF cDNA In an attempt to replicate the characteristic patterns of multimers from the plasma of heterozygous individuals, the coexpression of WT and mutant full-length vWF were carried out with use of several different proportions between WT and mutant plasmids for transfection. The characteristic vWD 2A/IID multimer pattern a decrease in large
multimers and an extra central band between individual multimerswas
replicated by using a ratio of 10 µg WT to 10 µg mutant plasmid. A
ratio of 5 µg WT and 15 µg mutant plasmid replicated the
heterozygous phenotype of the vWD 3 mutation (Figure 5B). Heterozygous
expression of the vWD 2A/IIE mutation by using different proportions of
WT to mutant plasmid resulted in a relative decrease in larger
multimers and a lack of ultralarge multimers compared with the WT
results. However, intervening bands were not detected, even at the
lowest ratio (1:39) of WT to mutant plasmid concentration (Figures
6 and 7).
We explored the posttranslational processing of vWF monomers into
dimers and multimers in detail by using recombinant expression of
mutant and WT vWF. Intermolecular bonding of normal vWF is provided
first by the dimerization site at the vWF carboxy-terminal and then by
the multimerization site at the amino-terminal. Dimerization at the
carboxy-terminal of normal vWF monomers in the endoplasmic reticulum
(ER) appears to be quantitative, and only dimers are expected to be
further transported to the Golgi and post-Golgi region where the
multimerization process occurs.32,33 Consequently, normal
multimers consist only of even numbers of subunits (Figure 8).
Dimerization and intermolecular bonding at the vWF amino-terminal are processes that can occur independently of each other.26 Thus, in the case of a dimerization defect at the carboxy-terminal, we would nevertheless expect the formation of dimers by disulfide bonding at the amino-terminal. To assess the effects of the mutations at the carboxy-terminal on the dimerization process of vWF monomers and on the intermolecular disulfide bonding at the amino-terminals of vWF dimers to multimers, we first expressed only the carboxy-terminal fragment II that harbors the dimerization site. All 3 mutations in exon 52 of the vWF gene affected cysteine residues and severely impaired dimerization of vWF monomers, as demonstrated by the synthesis of only monomeric mutated fragment II compared with the dimeric WT (Figure 4). We then did 2 different transfection experiments with mutant and WT full-length vWF cDNA. First, to mimic a homozygous mutation, we used only mutant vWF cDNA for transfection, and second, to reproduce the heterozygous state, we conducted cotransfection studies of mutant and WT vWF. In spite of the dimerization defect, the homozygous expression of mutant full-length vWF resulted in synthesis of dimeric protein, suggesting that the disulfide bonding at the amino-terminal of the mutant vWF was intact. This finding confirms a previous report that amino-terminal intersubunit disulfide bonding occurs independently of dimerization at the carboxy-terminal.26 We also observed small amounts of tetramers in all mutants studied (Figure 5A), a result that suggests the presence of a functionally incomplete block of dimerization, possibly based on the additional carboxy-terminal cysteine residues involved in intersubunit bonding; however, we did not observe analogous findings in expression studies of the carboxy-terminal fragment II. As expected, expression of full-length WT vWF resulted in synthesis of the complete set of multimers. Using the same seeding concentration of 4 × 105 COS-7 cells in each of the transfection experiments, we obtained different yields of vWF:Ag for mutant and WT vWF. The lowest values were for the 8566delC mutation and the vWD 3 mutation C2754W, and a concentration close to that for recombinant WT vWF was obtained for the vWD 2A/IID mutation C2773R. Functional studies of the recombinant mutant dimeric vWF revealed severely impaired vWF:CBA but normal FVIII binding activity. Correspondingly, in the patient with vWD 2A/IID, normal vWF:Ag levels correlated with normal FVIII:C values, whereas in the patients with vWD 2A/IIE or vWD 3, low or undetectable vWF:Ag levels corresponded with low FVIII:C values (Table 1). Coexpression of WT and mutant vWF should theoretically lead to the formation of normal dimers and aberrant monomers in the ER. If both dimers and monomers were subsequently transported to the Golgi compartment, in the second step, further intermolecular disulfide bonding at the vWF amino-terminal could result in the formation of either dimers (made up of aberrant monomers), trimers (made up of one aberrant monomer and a normal dimer), or normal tetramers (consisting of 2 normal dimers). In the third step, aberrant dimers cannot further multimerize because they only carry the defect dimerization domain at both terminals, whereas aberrant trimers can bind to either an aberrant monomer or a normal dimer forming aberrant tetramers and aberrant pentamers. The normal tetramers can further expand to aberrant pentamers, normal hexamers, and so forth (Figure 8). Thus, along with the formation of multimers with an even number of subunits, it is possible that multimers with an odd number of subunits are formed. The vWF multimer patterns from heterozygous relatives of the patients
with vWD 3 and, in an even more pronounced fashion, heterozygous
patients with vWD 2A/IID, showed characteristic intervening bands that
are clearly distinct from the bands contributing to the usual triplet
structure of normal vWF multimers.6,34 This phenotype was
replicated through coexpression of recombinant WT and mutant
full-length vWF (Figure 5B). Our results provide evidence that these
intervening bands represent multimers with an odd number of subunits.
The absence of HMWM in the patient with vWD 2A/IID may be explained on
a statistical basis by an increased probability that aberrant C2773R
monomers Neither plasma vWF from the patient with vWD 2A/IIE nor the respective recombinant vWF from the coexpression experiment had intervening bands to indicate multimers with odd numbers of subunits. The reason for this is not clear. However, the 8566delC mutation differs from the 2 other defects described in this study in its consequences, which are rather complex. The frameshift completely alters subsequent codons, substitutes 6 cysteines with 7 others at aberrant positions, and predicts an elongated translation product. Thus, along with elimination of C2773, the cysteine that is mutated in the patient with vWD 2A/IID, there is elimination of cysteines at positions 2774, 2788, 2804, 2806, and 2811, of which C2811 could also be part of an intermolecular disulfide bond (although its mutation to alanine permitted formation of dimers in recombinant expression experiments).35 In addition, the generation of 7 new cysteines in the predicted aberrant sequence could give rise to alternative intramolecular disulfide bonds contributing to the unique vWD 2A/IIE phenotype in comparison to the other dimerization defects. It is possible that the resulting mutant pro-peptide could also influence the subsequent multimerization process at the amino-terminal, which would further impair the binding of aberrant monomers and formation of multimers with odd numbers of subunits. Another reason for the lack of intervening bands could be a very low expression of the second allele. Normal multimers derived from this allele would not be abundant and could be readily saturated at both amino-terminal sites with the more abundant mutant 8566delC monomers, resulting in a preponderance of multimers with an even number of subunits. The electrophoretic pattern of homozygous recombinant 8566delC vWF did not differ much from those of the 2 other homozygously expressed vWD defects, but in contrast to those defects, only small amounts of WT DNA were sufficient to rescue most of the normal phenotype. This was demonstrated through transfection with different proportions of WT to 8566delC mutant DNA (Figures 6 and 7). Even transfection proportions of 1 part WT and 39 parts mutant DNA did not completely replicate the multimer pattern observed in patient 0103, and the only similarities to the in vivo phenotype were absence of ultralarge multimers normally observed in WT vWF expression experiments and a relative decrease in the concentration of large multimers compared with WT vWF (Figures 6 and 7). These findings suggest that expression of vWF derived from the patient's second putative vWD allele was very low, albeit not completely absent. We sequenced the complete coding region and flanking introns of the vWF gene without detecting a second mutation. Therefore, we do not have experimental data that explain the lack of intervening bands in this particular patient with vWD 2A/IIE. The shared underlying defect of vWF dimerization is an interesting feature of the manifestation of different vWD types and subtypes. In the case of the homozygous missense mutation C2754W, the defect may even result in the phenotype of severe vWD 3 clinically and with regard to vWF laboratory findings. Minute amounts of vWF were detected only in the patient's platelets by high-sensitivity luminescent multimer analysis (Figure 1). Possibly, in contrast to the situation in the circulation, from which vWF is cleared by proteolysis and consumption, platelets might be regarded as a protective environment for vWF. Compared with plasma, the higher concentration of mutant vWF in COS-7 cells might reflect the nonphysiologic conditions of in vitro protein expression in heterologous cells, eg, absence of the vWF-specific metalloprotease in the cell-culture medium (unpublished data). A study of the possible role of the vWF carboxy-terminal cysteine residues in the dimerization process was done by Katsumi et al.35 The results suggested that C2771, C2773, and C2811 are the only cysteines that could form the intersubunit bonds between vWF monomers in the cystine knot-like (CK) domain at the vWF carboxy-terminal, a common motive found in the dimerization region of several proteins. One of these cysteines, C2773, is mutated in our patient with vWD 2A/IID, whereas C2771 was found to be mutated in another patient with vWD 2A/IID.36 Furthermore, in our patient with vWD 2A/IIE, C2773 was the first amino acid predicted to be altered by the underlying frameshift mutation. Thus, our data obtained by studying patients are in perfect agreement with the results of a biochemical study of the cysteine residues directly involved in vWF dimerization.35 According to that study, C2754, the cysteine mutated in our patient with vWD 3, is probably not directly involved in intersubunit binding but rather is involved in an intramolecular disulfide bond.35 Nevertheless, the mutation C2754W clearly results in a dimerization defect. Interestingly, C2754 is bound to C2803 and both cysteines contribute to the CK consensus sequence of vWF. A homozygous mutation at C2803 (C2803R) has been reported.37 Its consequences are similar to those of C2754W and comprise the presence of only dimers, both in plasma and in recombinant mutant vWF in the homozygous patient, and the presence of characteristic intervening bands, suggesting multimers with an odd number of individual subunits in heterozygous individuals. Our results suggest that the 3 mutations involving cysteines in the CK domain at the vWF carboxy-terminal cause severe defects of dimerization in different types of vWD. The mutation C2773R eliminates an intermolecular disulfide bond in the patient with vWD 2A/IID, and C2754W eliminates an intramolecular bond as part of the vWF CK consensus sequence in the patient with vWD 3. The mutation 8566delC (vWD 2A/IIE) involves C2773 and several other cysteines that may be important for dimerization in the vWF CK domain.
Submitted March 7, 2000; accepted November 30, 2000.
Supported by the Deutsche Forschungsgemeinschaft, grants DFG Schn 325/4-1 and DFG Schn 325/4-2.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Reinhard Schneppenheim, University Children's Hospital Hamburg, Department of Pediatric Hematology and Oncology, D-20246 Hamburg, Germany; e-mail: schneppenheim{at}uke.uni-hamburg.de.
1. Shelton-Inloes BB, Chehab FF, Mannucci PM, Federici AB, Sadler JE. Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest. 1987;79:1459-1465. 2. Zhang ZP, Lindstedt M, Falk G, Blomback M, Egberg N, Anvret M. Nonsense mutations of the von Willebrand factor gene in patients with von Willebrand disease type III and type I. Am J Hum Genet. 1992;51:850-858[Medline] [Order article via Infotrieve]. 3. Schneppenheim R, Krey S, Bergmann F, Bock D, et al. Genetic heterogeneity of severe von Willebrand disease type III in the German population. Hum Genet. 1994;94:640-652[Medline] [Order article via Infotrieve].
4.
De Marco L, Girolami A, Zimmerman TS, Ruggeri ZM.
Interaction of purified type IIB von Willebrand factor with the platelet membrane glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and initiates aggregation.
Proc Natl Acad Sci U S A.
1985;82:7424-7428
5.
Nishino M, Girma JP, Rothschild C, Fressinaud E, Meyer D.
New variant of von Willebrand disease with defective binding to factor VIII.
Blood.
1989;74:1591-1599
6.
Schneppenheim R, Brassard J, Krey S, et al.
Defective dimerization of von Willebrand factor subunits due to a Cys
7.
Gaucher C, Dieval J, Mazurier C.
Characterization of von Willebrand factor gene defects in two unrelated patients with type IIC von Willebrand disease.
Blood.
1994;84:1024-1030 8. Holmberg L, Karpman D, Isaksson C, Kristoffersson AC, Lethagen S, Schneppenheim R. Ins405AsnPro mutation in the von Willebrand factor propeptide in recessive type 2A (IIC) von Willebrand's disease. Thromb Haemost. 1998;79:718-722[Medline] [Order article via Infotrieve]. 9. Ginsburg D, Sadler JE. von Willebrand disease: a database of point mutations, insertions, and deletions: for the Consortium on von Willebrand Factor Mutations and Polymorphisms, and the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1993;69:177-184[Medline] [Order article via Infotrieve].
10.
Furlan M, Robles R, Lamie B.
Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.
Blood.
1996;87:4223-4234 11. Sadler JE. A revised classification of von Willebrand disease. Thromb Haemost. 1994;71:520-525[Medline] [Order article via Infotrieve]. 12. Zimmerman TS, Dent JA, Ruggeri ZM, Nannini LH. Subunit composition of plasma von Willebrand factor: cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE). J Clin Invest. 1986;77:947-951. 13. Ivy AC, Shapiro PF, Melnick P. The bleeding tendency in jaundice. Surg Gynecol Obstet. 1935;60:781. 14. Hardisty RM, McPherson JC. A one-stage factor VIII (antihaemophilic globulin) assay and its use on venous and capillary plasma. Thromb Diath Haemorrh. 1962;7:215-229. 15. Mazurier C, Parquet Gernez A, Goudemand M. Enzyme-linked immunoabsorbent assay of factor VIII-related antigen: interest in study of Von Willebrand's disease. Pathol Biol. 1977;25:18-24. 16. Macfarlane DE, Stibbe J, Kirby EP, Zucker MB, Grant RA, McPherson J. A method for assaying von Willebrand factor (ristocetin cofactor) [letter]. Thromb Diath Haemorrh. 1975;34:306-308[Medline] [Order article via Infotrieve]. 17. Brown JE, Bosak JO. An ELISA test for the binding of von Willebrand antigen to collagen. Thromb Res. 1986;43:303-311[CrossRef][Medline] [Order article via Infotrieve].
18.
Ruggeri ZM, Zimmerman TS.
The complex multimeric composition of factor VIII/von Willebrand factor.
Blood.
1981;57:1140-1143
19.
Schneppenheim R, Plendl H, Budde U.
Luminography 20. Schneppenheim R, Budde U, Krey S, et al. Results of a screening for von Willebrand disease type 2N in patients with suspected haemophilia A or von Willebrand disease type 1. Thromb Haemost. 1996;76:598-602[Medline] [Order article via Infotrieve]. 21. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory; 1989.
22.
Saiki RK, Gelfand DH, Stoffel S, et al.
Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase.
Science.
1988;239:487-491 23. Mancuso DJ, Tuley EA, Westfield LA, et al. Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction. Biochemistry. 1991;30:253-269[CrossRef][Medline] [Order article via Infotrieve].
24.
Orita M, Iwahana H, Kanazawa H, Hayashi K, Sekiya T.
Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms.
Proc Natl Acad Sci U S A.
1989;86:2766-2770 25. Budowle B, Chakraborty R, Giusti AM, Eisenberg AJ, Allen RC. Analysis of the VNTR locus DIS80 by the PCR followed by high resolution PAGE. Am J Hum Genet. 1991;48:137-144[Medline] [Order article via Infotrieve]. 26. Sadler JE, Ginsburg D. A database of polymorphisms in the von Willebrand factor gene and pseudogene: for the Consortium on von Willebrand Factor Mutations and Polymorphisms and the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 1993;69:185-191[Medline] [Order article via Infotrieve]. 27. Voorberg J, Fontijn R, van-Mourik JA, Pannekoek H. Domains involved in multimer assembly of von Willebrand factor (vWF): multimerization is independent of dimerization. EMBO J. 1990;9:797-803[Medline] [Order article via Infotrieve].
28.
Mancuso DJ, Tuley EA, Westfield LA, et al.
Structure of the gene for human von Willebrand factor.
J Biol Chem.
1989;264:19514-19527 29. Bonthron DT, Handin RI, Kaufman RJ, et al. Structure of pre-pro-von Willebrand factor and its expression in heterologous cells. Nature. 1986;324:270-273[CrossRef][Medline] [Order article via Infotrieve].
30.
Roest PA, Roberts RG, Sugino S, van Ommen GJ, den Dunnen JT.
Protein truncation test (PTT) for rapid detection of translation-terminating mutations.
Hum Mol Genet.
1993;2:1719-1721
31.
Schneppenheim R, Brassard J, Budde U, Krey S, Schwaab R, Oldenburg J.
Defective dimerization of von Willebrand factor 32. Wagner DD, Bonfanti R. von Willebrand factor and the endothelium. Mayo Clin Proc. 1991;66:621-627[Medline] [Order article via Infotrieve].
33.
Wagner DD, Mayadas T, Marder VJ.
Initial glycosylation and acidic pH in the Golgi apparatus are required for multimerization of von Willebrand factor.
J Cell Biol.
1986;102:1320-1324
34.
Kinoshita S, Harrison J, Lazerson J, Abildgaard CF.
A new variant of dominant type II von Willebrand's disease with aberrant multimeric pattern of factor VIII-related antigen (type IID).
Blood.
1984;63:1369-1371
35.
Katsumi A, Tuley EA, Bodó I, Sadler JE.
Localization of disulfide bonds in the cystine knot domain of human von Willebrand factor.
J Biol Chem.
2000;275:25585-25594 36. Enayat MS, Surdhar GK, Theophilus BDM, Williams DM, Hill FGH. A new candidate mutation causing type IID von Willebrand disease in 3 patients in 3 generations of the same family [abstract]. Thromb Haemost. 1997;78(suppl):655. 37. Montgomery RR, Jozwiak MA, Hutter JJ, Endres JL, Foster PA, Friedman KD. A homozygous variant of von Willebrand factor (vWF) that fails to C-terminal dimerize resulting in loss of vWF multimers larger than dimer [abstract]. Blood. 1999;94:622a.
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  J. J. Michiels, Z. Berneman, A. Gadisseur, M. van der Planken, W. Schroyens, A. van de Velde, and H. van Vliet Classification and Characterization of Hereditary Types 2A, 2B, 2C, 2D, 2E, 2M, 2N, and 2U (Unclassifiable) von Willebrand Disease Clinical and Applied Thrombosis/Hemostasis, October 1, 2006; 12(4): 397 - 420. [Abstract] [PDF]
|
|
|
|
|
|
J. J. Michiels, Z. Berneman, A. Gadisseur, M. van der Planken, W. Schroyens, A. van de Velde, and H. van Vliet Characterization of Recessive Severe Type 1 and 3 von Willebrand Disease (VWD), Asymptomatic Heterozygous Carriers Versus Bloodgroup O-Related von Willebrand Factor Deficiency, and Dominant Type 1 VWD Clinical and Applied Thrombosis/Hemostasis, July 1, 2006; 12(3): 277 - 295. [Abstract] [PDF]
|
|
|
|
 |
|
 R. K. Pruthi A Practical Approach to Genetic Testing for von Willebrand Disease Mayo Clin. Proc., May 1, 2006; 81(5): 679 - 691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Schneppenheim, U. Budde, F. Oyen, D. Angerhaus, V. Aumann, E. Drewke, W. Hassenpflug, J. Haberle, K. Kentouche, E. Kohne, et al. von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP Blood, March 1, 2003; 101(5): 1845 - 1850. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
Arg mutation in type IID von Willebrand disease.
Proc Natl Acad Sci U S A.
1996;93:3581-3586